Our top pick for
Alimera Sciences, Inc is a drug manufacturers—specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 122 staff and has a trailing 12-month revenue of around USD$54.8 million.
|52-week range||USD$0.1973 - USD$9.98|
|50-day moving average||USD$5.1999|
|200-day moving average||USD$5.506|
|Wall St. target price||USD$13.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.303|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Alimera Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alimera Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alimera Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Alimera Sciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Alimera Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.1 million.
The EBITDA is a measure of a Alimera Sciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$54.8 million|
|Gross profit TTM||USD$47.3 million|
|Return on assets TTM||-1.94%|
|Return on equity TTM||0%|
|Market capitalisation||USD$23.3 million|
TTM: trailing 12 months
There are currently 31,489 Alimera Sciences shares held short by investors – that's known as Alimera Sciences's "short interest". This figure is 15.6% down from 37,310 last month.
There are a few different ways that this level of interest in shorting Alimera Sciences shares can be evaluated.
Alimera Sciences's "short interest ratio" (SIR) is the quantity of Alimera Sciences shares currently shorted divided by the average quantity of Alimera Sciences shares traded daily (recently around 16315.544041451). Alimera Sciences's SIR currently stands at 1.93. In other words for every 100,000 Alimera Sciences shares traded daily on the market, roughly 1930 shares are currently held short.
However Alimera Sciences's short interest can also be evaluated against the total number of Alimera Sciences shares, or, against the total number of tradable Alimera Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alimera Sciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Alimera Sciences shares in existence, roughly 10 shares are currently held short) or 0.007% of the tradable shares (for every 100,000 tradable Alimera Sciences shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alimera Sciences.
Find out more about how you can short Alimera Sciences stock.
We're not expecting Alimera Sciences to pay a dividend over the next 12 months.
Alimera Sciences's shares were split on a 1:15 basis on 15 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.
Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $0.1973 up to $9.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.9983. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.